Survival and prognostic analysis
DSS, colorectal neuroendocrine neoplasms
After a median follow-up time of 74 months (95%CI: 70-78), the median OS was 42 months (95%CI 32-57) among all 668 patients. After a median follow-up time of 68 months (95%CI: 66-73), the median DSS was 79 months (95%CI 45-not available [NA]) among all patients. In our study of the SEER dataset, the reason why NA contains in the 95% CI of DSS and other subgroup survival analyses is that the follow-up time was shorter than the median time of the respective group. The Kaplan-Meier curves of OS and DSS for all patients in the SEER dataset were represented in For further prognostic analysis, the 688 patients with CRNENs were randomly divided into a training cohort (n=468) and a validation cohort (n=200). Patient baseline characteristics between the two cohorts were well-balanced (Univariate and multivariate Cox analysis of OS of the II-IV stage patients with CRNENs.* Others refer to American Indians/Alaskan Native Americans, Asians or Pacific Islanders and UnkonwnCRNENs, colorectal neuroendocrine neoplasms; grade: well differentiated (G I), moderately differentiated (G II), poorly differentiated (G III) and undifferentiated (G IV).